Clinical Outcomes of Assisted Reproductive Techniques Using Cryopreserved Gametes and Embryos in Human Medicine by Waterstone, Max et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Clinical Outcomes of Assisted Reproductive Techniques
Using Cryopreserved Gametes and Embryos in Human
Medicine
Max Waterstone, Amandine Anastácio and
Kenny A. Rodriguez-Wallberg
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.80627
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
     
 .  i ll
i i l i f i  i  il l     f  
Abstract
The methods of cryopreservation play a key role in assisted reproductive technique 
(ART) treatments, as they increase the efficacy of the treatments by allowing banking of 
supernumerary embryos for later use. It has been recently proposed that these methods 
could also increase the safety of ART treatments, by reducing complications such as ovar-
ian hyperstimulation during early pregnancy; thus, the policy of total freeze for later 
differed transfer of embryos has been proposed. Also of great importance, cryopreserva-
tion of oocytes and spermatozoa has permitted gamete storage for long term facilitating 
practical routines such as the gamete banking for third-party reproductive treatment. 
In this chapter, the clinical indications and treatment outcomes will be revised and data 
updated on the safety of using cryopreservation methods in ART treatments.
Keywords: cryopreservation methods, assisted reproductive technique (ART) 
treatment, pregnancy, embryos, ovarian hyperstimulation
1. Introduction
The development of cryopreservation techniques has made possible the use of frozen and 
thawed gametes and embryos aiming at reproduction, by means of assisted reproductive 
techniques (ART). Cryopreservation allows to banking gametes for later use, including also 
the possibility to be used by other individuals, as in donor treatments. Effective techniques 
such as in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI), worldwide 
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applied, offer a high efficacy by the creation of supernumerary embryos. As recognised 
downsides of IVF/ICSI treatments include the high prevalence of perinatal complications due 
to multiple births, the recommended practice of transferring fewer embryos in the fresh IVF 
treatment cycle, with the goal of performing single embryo transfer and the cryopreservation 
of remaining embryos for their later use in frozen-thawed cycles, one at a time, is currently 
the trend [1]. The cumulative chance to achieve pregnancy and live-birth through IVF/ICSI 
treatments is thus enhanced by the later use of thawed embryos in separate treatments.
The methods for cryopreservation of embryos and gametes have demonstrated effective and 
safe, and have developed towards the achievement of a clinically established level. These meth-
ods are also currently being offered to patients suffering of cancer, due to the risk of infertility 
associated with certain cancer treatments, or to individuals with conditions that have an inher-
ent risk of premature gonadal insufficiency and infertility, aiming at fertility preservation [2].
Although embryo cryopreservation has historically been regarded as the first-choice technique 
for fertility preservation, social, ethical and legal reasons usually restrict its use to couples who 
have entered into a committed long-term relationship. However, women without a partner 
may attempt this possibility using a sperm donor. Furthermore, this issue has also been shown 
to translate to fertility preservation undertaken electively, with one study finding that >80% of 
patients undergoing oocyte preservation by choice were single at the time, and that lack of a 
partner was by far the most common reason for not pursuing child-bearing earlier [3].
As such, the cryopreservation of gametes affords individuals an increased level of reproduc-
tive autonomy, and ensures that fewer patients are faced with the extraordinarily difficult 
decision of later reproducing with a partner who may no longer be ideal, or not reproducing 
at all. Here, the most common indications for gamete cryopreservation in both males and 
females and embryo cryopreservation will be discussed, along with their clinical outcomes, 
necessary considerations and future perspectives.
2. Current status of fertility preservation by cryopreservation of 
gametes
Although semen cryopreservation has remained an established technique for many years, the 
cryopreservation of mature oocytes was considered experimental by the American Society for 
Reproductive Medicine (ASRM) until 2013 [4]. As such, this relatively recent development 
has paved the way for an explosion of social fertility preservation (‘social freezing’), found 
by a HFEA report to have increased more than two-fold between 2013 and 2016. In fact, a 
10% increase in the number of egg freezing cycles was reported from 2015 to 2016 [5]. In a 
field which was once dominated by fertility preservation following medical diagnosis, this 
represents a dramatic paradigm shift, which must be regulated to ensure transparency for, and 
protection of, the prospective patient. This differs from traditional approaches to non-elective 
fertility preservation, where patients who may be younger or have no desire to delay child-
bearing are faced with a high likelihood of complete infertility following resolution of their 
disease. Therefore, such conditions encompass those that directly cause premature ovarian 
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insufficiency (POI) such as bilateral benign ovarian tumours, severe recurrent endometriosis or 
genetic disorders (e.g., Turner’s syndrome), and conditions that indirectly result in POI such as 
malignant or non-malignant diseases that require the administration of gonadotoxic chemo- or 
radiotherapy [6].
Whilst there is a tendency to focus primarily upon female infertility due to the intrinsically 
finite nature of female reproductive biology, it must be remembered that males are also dis-
tinctly susceptible to gonadotoxic agents, with one study reporting that up to 60% of male 
cancer survivors experience fertility impairment [7]. In fact, malignant diseases are amongst 
the most significant indirect contributors to infertility worldwide, with some of the most com-
monly-used classes of chemotherapeutics, alkylating agents, having been shown to induce 
POI in 42% of women treated [8]. The situation is further complicated by the widespread 
use of novel targeted therapies whose impact upon fertility is largely unknown [9]. These 
advances in cancer treatment efficacy (coupled with societal pressures to delay childbearing) 
have led to an increasing proportion of cancer survivors who wish to further add to their 
families, resulting in increased public awareness of treatment-induced subfertility, increased 
demand for fertility-preserving procedures, and the emergence of a brand-new field: oncofer-
tility [10, 11]. This new discipline is badly-needed, providing patients with essential informa-
tion that will impact upon their treatment decisions and future family planning, and aiming 
to disrupt the traditional lack of emphasis placed on iatrogenic infertility in the oncological 
sphere [11–13].
Another newly-emerging paradigm in gamete cryopreservation is its implementation as a 
timesaving method in fertility treatment. Age is the most significant determinant of IVF cycle 
outcome, meaning that older females who present for treatment may be considered for mul-
tiple consecutive rounds of ovarian stimulation and egg collection, thereby facilitating the 
freezing of large numbers of eggs which can later be fertilised and transferred [14]. This is a 
significant advantage for couples who may want multiple children, or who find the storage of 
a large number of embryos ethically questionable. It is open to debate whether this applica-
tion should be considered medical or social, but as technology advances, it is important we 
consider such applications that lie within the ‘grey areas’ of medicine.
2.1. Particular considerations regarding the cryopreservation of spermatozoa
Sperm cryopreservation is the only established fertility preservation method in post-pubertal 
males, and has been in clinical use for over 50 years [15]. Its early adoption to the clinical 
realm is attributed to the accidental discovery of the cryoprotective properties of glycerol on 
sperm cells, their abundance for experimental uses and their small size. This latter property 
is an extremely important one, reducing the likelihood of damaging intracellular ice crystal 
formation during the freezing process. Whilst cryopreservation by slow freezing protocol was 
the first method used successfully, it causes extensive chemical and physical damage to sperm 
cell membranes, with only 60% of sperm regaining motility post-thaw [16]. Comparative 
studies have demonstrated that non-standard methods of rapid freezing (vitrification) using 
liquid nitrogen give better post-thaw motility rates and alter protein expression profiles 
less, as well as being more time- and cost-efficient [17, 18]. Whilst both methods result in 
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a significant reduction in viability, the (generally) high number of spermatozoa per sample 
means that lower survival rates are acceptable. As such, either cryopreservation method may 
be used effectively. This relatively low bar for post-thaw viability contrast hugely with oocyte 
cryopreservation, where the numbers of gametes collected tends to be small, and therefore 
more stringent protocols and attrition rates are required.
Sperm samples for cryopreservation are usually obtained by masturbation, but if in the cases 
of azoospermia, males who are unable to provide a sample (e.g., for psychosocial or physical 
reasons) or those who have previously undergone a vasectomy, surgical techniques may be 
employed. These include epididymis aspiration, testicular needle biopsy (TESE) or needle 
aspiration (TESA), with TESE having impressive success rates of 85%, even following chemo-
therapy for testicular cancer [19]. It is important to note that although these methods of sperm 
retrieval are effective, all require that the patient is able to produce spermatozoa, even at 
dramatically decreased levels. Options are extremely limited for patients whose Sertoli cells 
are non-functional, or pre-pubertal males, with the cryopreservation and autotransplantation 
of spermatogonial stem cells (SSCs) still classified as experimental, but showing promise in 
animal models [20]. In vitro maturation of SSCs, or SSC derivation from induced pluripotent 
stem cells (iPSCs) are also avenues under investigation [21].
Whilst both the American Society of Clinical Oncology (and almost all other) guidelines rec-
ommend that fertility preservation be offered to pubertal males before commencement of 
gonadotoxic treatment, only 25% of eligible males in the relevant cohorts bank sperm. These 
statistics are surprisingly low, especially when one considers the generally non-invasive 
nature of semen sample collection, and the wealth of prospective studies supporting that 
viewpoint that the overwhelming majority of men diagnosed with cancer wish to have 
children later in life [22]. One such study reported that 43% of patients surveyed ranked 
reproducing as a ‘top 3’ life goal [23]. It is therefore apparent that a disconnect exists in male 
fertility preservation that is not present to the same degree in the female equivalent. This may 
be due to routinely poor counselling by clinicians, but it is also possible that the priorities of 
young male patients may not adequately reflect their later life goals, or that male stoicism 
might affect the decisions made. Equally, the perceived high cost of cryopreservation and 
storage might have a role to play, even though robust cost-benefit analyses have shown sperm 
cryopreservation to be more cost-effective than post-therapeutic fertility management [19]. It 
has been evidenced that long-time storage does not seem to affect the fertilisation potential of 
sperm, as recently reported after 40 years of storage [24].
2.2. Particular considerations regarding the cryopreservation of oocytes
In contrast to spermatozoa, mature (MII) oocytes are large, fragile cells that are much more 
susceptible to water retention and ice crystal-mediated damage. Furthermore, addition of 
cryoprotectants may result in osmotic stress, with the cumulative effect of these stressors 
manifesting as thickening of the zona pellucida, premature cortical granule exocytosis and 
meiotic spindle disruption [25, 26]. Although this disruption of the meiotic spindle appears 
to be transient in almost all cases, there is robust evidence to show that cryopreservation 
negatively impacts oocyte gene expression and proteomics, with some cryoprotectants even 
shown to alter maternally-derived proteins which support early oocyte development [27–29]. 
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The net result of this is a ‘stressed’ oocyte which is difficult for spermatozoa to penetrate and 
fertilise. As such, the clinical applications of oocyte cryopreservation were limited until the 
inception of the ICSI technique in 1992 [30], with the first pregnancy derived from frozen 
oocytes following in 1997 [31].
Another quantum leap forward in the efficacy of oocyte cryopreservation came with refine-
ment of freezing protocols. Similar to the paradigm change seen in spermatozoa cryopreser-
vation, vitrification (fast freezing) techniques were pioneered, first producing a live birth in 
1999, and then being further improved by Japanese groups in 2003 [32, 33]. In contrast to 
the small increase in efficacy seen with the introduction of vitrification in spermatozoa cryo-
preservation, however, vitrification of oocytes seems to greatly increase post-thaw oocyte sur-
vival and fertilisation rates, with a 2014 Cochrane review finding a relative increase in oocyte 
survival of 29%, and a 19% increase in fertilisation [34]. An additional meta-analysis of three 
RCTs in 2016 reported a 16.1% increase in survival (RR = 1.23, 95% CI: 1.02–1.49; P = 0.031) [35]. 
The efficacy of the vitrification technique was further confirmed when a large prospective 
study of Spanish egg-donation programmes could not detect any statistically significant dif-
ference between using fresh donor eggs, when compared to vitrified frozen eggs [36]. It is 
important to note, however, that both of these techniques are inherently operator-dependent; 
with vitrification especially variable due to the need to complete the process within seconds [37]. 
This is an important caveat, and highlights the importance of training and upskilling, espe-
cially when considering the variable experience that operators may have within the same 
fertility clinic. It must also be clarified that the survival rates of oocytes (and the number 
collected) are likely dependent on the age and disease status of the donor, meaning that the 
extremely high survival rates of thawed oocytes reported by some studies on donor eggs (in 
excess of 96%), may not be truly representative for a significant proportion of patients who 
undergo fertility-preserving treatment [38].
It is clear, therefore, that the path to the clinic for oocyte cryopreservation has not been a 
straightforward one, with the early, highly-ineffective methods of oocyte cryopreservation 
making it an unrealistic and imprudent option for females in urgent need of fertility preserva-
tion, such as oncology patients. Cancer in reproductive age is twice as common in females 
as in males, and more than half of those diagnosed are expected to undergo treatment that 
compromises their fertility [39]. One large retrospective study highlighted this, indicating 
that whilst the incidence of treatment-related acute ovarian failure (AOF) was approximately 
10%, these figures greatly misrepresent the total age-specific impact on fertility, with 40% of 
those not reporting AOF encountering infertility by the age of 35 [40]. Furthermore, the prob-
ability of early menopause was ‘at least’ 25% by age 30 [40]. It is likely, therefore, that effects 
on fertility may often relate to a reduction in the overall number of primordial follicles, and 
may therefore remain undetected until later in life. In a society where increasing numbers of 
women are choosing to delay childbearing, this may mean that women who are presumed 
to have normal reproductive activity following resumption of menstruation may not try to 
conceive as early as they are able to, and then later encounter difficulty.
It is important to consider that patients undergoing fertility-compromising cancer treatments 
may only have sufficient time for one round of ovarian stimulation and egg collection before 
their treatment must begin. This process of controlled ovarian stimulation (COS) followed by 
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egg collection generally takes approximately 2 weeks to complete, with patients able to start 
chemotherapy within 48 h of completion. Whilst concerns had initially been raised about the 
administration of such high doses of exogenous gonadotrophins to patients with hormone-
sensitive cancers (e.g. breast, ovarian), effective and safe stimulation protocols using aroma-
tase inhibitors have been developed and shown to result in no increased risk of recurrence 
in breast cancer, after a mean 5-year follow-up period [41]. In addition, the use of GnRH 
antagonist regimens (in place of the usual GnRH agonist regimens) allow ovarian stimulation 
to be started at any point in the menstrual cycle (‘random-start protocols’), thereby minimis-
ing treatment delays. These GnRH antagonist regimens have been shown to result in the 
collection of similar numbers of mature oocytes and produce similar fertilisation rates [42]. 
Moreover, they have been shown to result in a lower risk of ovarian hyperstimulation syn-
drome (OHSS) than conventional protocols [43].
As such, refinements in cryopreservation techniques and stimulation protocols represent 
incredibly important steps for cancer (and elective) patients, increasing both the safety of 
oocyte collection and the likelihood of a live birth following completion of treatment.
2.3. Clinical outcomes of using cryopreserved gametes
As outlined above, the cryopreservation of gametes is a technically difficult and expensive 
process. As such, it is essential that the true success rates of these procedures be analysed using 
clinical endpoints, in order to prevent delays to treatment, unnecessary harm to patients and 
to disrupt the growing belief amongst the general proportion that egg freezing constitutes an 
infallible ‘insurance policy’ against age-related fertility decline.
In order to assess the success of cryopreservation we must first examine the parameters by 
which success is gauged. The most realistic way to evaluate the efficacy of cryopreservation 
techniques (and indeed individual clinics) is through the comparison of live births achieved 
per oocyte thawed. Although this may seem obvious, there is a growing propensity for some 
clinics (especially those who derive a significant proportion of their income from social egg 
freezing) to display these statistics in a manner that makes them appear more impressive. For 
example, some success rates might be represented using clinical pregnancy rates per thaw 
cycle; with some studies reporting this to be as high as 78% [44]. This figure is not an accurate 
representation of the reality faced by most patients, with the largest reported study of 3610 
vitrified oocytes producing an oocyte survival rate of 90%, translating to a clinical pregnancy 
rate of 48% and an ‘oocyte-to-baby’ rate of just 6.5% [45]. If this same study were to be pre-
sented alternatively, it could be quoted as a delivery rate of 78.8% per oocyte donation cycle. 
As such, it is clear that there must be further efforts to homogenise how ‘success’ is calculated, 
and increased scrutiny of how these results are presented to potential patients. It is essential, 
also, to note that this data (and indeed almost all data on oocyte cryopreservation) has been 
generated from oocyte donation programmes. This is significant because oocyte donors tend 
to be carefully-selected, young individuals, whose eggs are likely to be of greater quality 
than the average patient wishing to engage in autologous fertility preservation. In fact, this 
viewpoint is supported by findings that only 32% of patients freezing their eggs were below 
the age of 35, and recent data showing reduced yield of oocytes collected in oncology patients 
versus matched controls [5, 38, 44]. As such, it is likely that the true likelihood of a successful 
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live birth for patients in these groups is significantly lower than the figures generated by cur-
rent data. It is essential, therefore, that the increasing availability of data from non-donation 
sources be interpreted and used to validate the statistics that are currently quoted.
The largest study using data collected from outside of egg donation programmes was carried 
out by Cobo et al., who examined the reproductive success of 1468 women undergoing elec-
tive oocyte cryopreservation for non-oncologic reasons [46]. Their data clearly demonstrates 
the impact of age at freezing upon potential success, with those who froze at or before the age 
of 35 having a 53.9% likelihood of a live birth per ET, whilst those freezing at or above the age 
of 36 had a 22.9% chance. This viewpoint was echoed by a recent HFEA report, who described 
patient age at freezing as ‘the most important factor’, whilst age at thaw was not determined 
to have any statistically significant impact [5]. The same study also demonstrated the impor-
tance of the number of oocytes obtained to vitrify in increasing chanced of a live birth, with an 
increase from 5 to 8 oocytes producing the most significant increase in LBR (8.4% per oocyte 
if <35). Whilst an average ‘oocyte-to-baby’ ratio is omitted, it is estimated to be significantly 
lower than the 6.5% achieved in donor programmes. Whilst this is an interesting figure, it is 
likely that it does not provide as clear a picture of the factors that impact oocyte viability as 
that provided by age-bracket stratification.
Consequently, we can conclude that the number of viable oocytes available for fertilisa-
tion is a clear determinant of the likelihood of successful pregnancy. The technique used to 
freeze and thaw the oocytes retrieved is thus of the utmost importance, with a multitude 
of studies confirming the advantages provided by vitrification protocols, both in terms of 
post-thaw oocyte survival and reported pregnancy rate. In fact, multiple studies reported 
the clinical pregnancy rate (CPR) to more than double when compared to slow-freezing 
protocols [47, 48]. In addition, there is increasing scrutiny on the impact that the rate of 
warming can have on post-thaw oocyte survival and characteristics. In fact, Mazur and 
Seki reported oocyte survival >80% when ultra-rapid warming was carried out, even when 
using traditional slow-freeze protocols. Further expanding on this, they demonstrated that 
such methods could be used to reduce the concentrations of cytotoxic chemoprotectant 
required for the vitrification process [49]. Interestingly, a recent meta-analysis of five stud-
ies concluded that there was no significant difference between the fertilisation rates, embryo 
cleavage or pregnancy rates achieved when using fresh versus vitrified oocytes [50]. This 
viewpoint is supported by recent data supplied by the HFEA, who concluded that the birth 
rate per embryo transfer (PET) was rising to over 19%, and within 2% of the overall IVF birth 
rate PET [5]. In addition, multiple studies have demonstrated that the length of storage has 
no effect on pregnancy rates or outcomes [45, 51]. As such, it is reasonable to conclude that 
cryopreservation techniques have advanced to such a stage that significant future improve-
ments in success rates will likely relate to methods of increasing the yield of oocytes col-
lected per stimulation cycle, or in the methods used to select the embryos to be transferred.
The above discussion is necessarily focused on female gametes, as spermatozoa quality has 
traditionally been seen to be of less importance owing to the large number usually obtained 
per collection and their high survival rate. It is also worth noting that studies have found no 
correlation between sperm quality and disease stage in oncology patients [52]. In addition, 
the advent of ICSI has meant that even ‘poor quality’ sperm samples with low motility scores 
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can be used to produce a viable embryo. That said, it is almost certain that there exist intrinsic 
variations in spermatozoa quality that currently evade detection, driving increased research 
into how we select the sperm we use for fertilisation, both in the context of conventional IVF, 
and in fertility preservation. The artificial techniques discussed have abrogated the physi-
ological selection methods inherent to the natural reproductive process, paving the way for 
a growing need for the ‘unnatural selection’ of favourable gametes via novel biomarkers or 
growth characteristics. Ongoing avenues of such research include the assessment of sperma-
tozoal DNA fragmentation rates (although evidence is not yet conclusive), and promising 
future avenues such as the stratification of sperm quality via spectrophotometric analytical 
techniques such as Raman spectroscopy [53]. In fact, the latter method would allow androlo-
gists to select spermatozoa on the basis of both their homeostatic and epigenetic context [54].
It follows that an essential aspect of any discussion on the clinical outcomes of gamete cryo-
preservation must be that of perinatal outcomes. It is often easy to rely on pregnancy rate 
as the sole benchmark of a successful preservation cycle, but serious consideration must also 
be given to whether the progeny created are morphologically, genetically and developmen-
tally ‘normal’. Reassuringly, a number of analyses, one of 165 pregnancies and another of 936 
infants, have found a comparable incidence of congenital abnormalities in infants born fol-
lowing oocyte vitrification, conventional IVF and natural pregnancy [55, 56]. There is also a 
growing body of evidence, however, that IVF may trigger epigenetic disruption in the develop-
ing embryo, potentially causing the slightly lower birth weights observed amongst children 
born as a result of these techniques [57]. That said, it is also possible that these differences are 
related solely to the increased ages of the patients within the IVF cohort. A long-established 
relationship exists between increased parental age and genetic dysfunction, with increased 
maternal age being linked to abnormal meiotic spindle function, and therefore the induction 
of gross chromosomal abnormalities such as Trisomy 21 (Down’s syndrome) [58]. Similarly, it 
has been shown that the higher prevalence of single point mutations seen in children born to 
fathers of more advanced age is attributable to the higher number of mitotic replications that 
these germ cells have experienced [59]. It is thought that this is a direct cause of the increased 
rates of neurodevelopmental disorders, leukaemias and stillbirths seen in this paternal cohort 
[60]. As such, although age has a strong positive correlation with adverse perinatal outcomes, 
no cryopreservation-specific (or indeed fertility treatment-specific) causal relationship has yet 
been reliably established.
In fact, the most common perinatal outcomes that are directly attributable to IVF are due 
to multiple pregnancies. These usually occur as a consequence of the transfer of more than 
one embryo, and may result complications such as premature birth, intrauterine death and 
conversion to caesarean section [61]. Whilst this, and complications associated with advanced 
maternal age, certainly remain considerations in the fertility preservation sphere, the patients 
concerned tend to have fewer options and less time to achieve a successful pregnancy, making 
the delivery of multiple children more serendipitous than it otherwise might be. Indeed, as 
the average age of childbearing increases (due, in part, to ART), it is arguable that discussion 
of such ‘difficult pregnancies’ will be of less future importance, as prospective patients will 
almost always opt to try to conceive in the face of an increased risk of poor perinatal outcome, 
instead of not attempting to conceive at all.
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In conclusion, although the oocyte conversion rates discussed above might seem extremely poor 
at the outset, it must again be stressed that modern assisted reproduction technologies circum-
vent the physiological selection mechanisms that serve to ensure only the most viable gametes 
survive. Success rates using cryopreserved gametes are almost comparable to those achieved 
using fresh gametes, and therefore it is reasonable to expect the efficacy of both techniques 
to advance in parallel as our knowledge and gamete selection methods improve. The Table 1 
presents several methods currently used to improving gamete selection for cryopreservation.
2.4. Societal and ethical aspects of cryopreserving gametes
Although the technical aspects of gamete cryopreservation have been discussed at length 
above, one must also consider the societal and ethical impact of such procedures. Gametes 
are incredibly prized cells; holding the genetic information is required to produce related off-
spring for those at high risk of fertility disruption. Therefore, the conditions under which they 





Traditionally, sperm selection via preparative techniques was 
undertaken post-thaw. There is increasing evidence, however, to 
show that such swim-up techniques should be performed before 
cryopreservation to produce the highest percentage of viable 
spermatozoa. It is theorised that cytokine release from immune 
cells that are inadvertently included in cryopreserved samples may 
damage spermatozoa quality, and that this could be avoided using 
these pre-freeze techniques. This viewpoint has  
been supported by data from recent trials.
Petyim et al. [111]
Rate of cooling As evidenced by the aforementioned increases in gamete 
quality using vitrification techniques, the rate of cooling during 
cryopreservation is extremely important. As such, efforts have been 
made to dramatically decrease the volume of the solution in which 
oocytes are vitrified (now 0.1–2 μL). To facilitate this, specialised 
carriers have been developed, including both open and closed 
systems. Comparative analysis of these two categories of systems 
has demonstrated similar oocyte survival rates, but significantly 
increased cytoplasmic vesicle presence (and theorised  
reduction in quality) in oocytes frozen using the closed system.
Bonetti et al. [112]
Low-CPA protocols Protocols that employ low concentrations of cryoprotectants have 
the potential to combine the positive aspects of vitrification and 
slow-freezing, without their respective associated disadvantages. 
Although such protocols have been impractically complex and time-
consuming, recent advances in quartz micro-capillary techniques are 
showing promise.
Choi et al. [113]
Single-gamete analysis Although not yet adequately optimised for clinical use, analysis of 
individual gametes has the potential to revolutionise how ART is 
carried out. The increasing need for artificial selection has meant that 
there is now increasing scrutiny on spectrophotometric and other 
non-invasive analytical techniques, some of which have been shown 
to provide adequate comparative analysis for oocyte quality and 
sperm DNA fragmentation rate. Whether this comparative analysis 
will be of clinical use, however, remains to be seen.
Davidson et al. [114]
Sanchez et al. [115]
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are stored, and the length of time which they can be stored for are of the utmost importance. 
Although legislative circumstances may vary from country to country, the HFEA permits 
storage of gametes or embryos for an initial maximum period of 10 years, with this being 
extended by 10 years at a time on a case-by-case basis up to a maximum of 55 years [61]. These 
limits are important to protect the wellbeing of prospective children, and to prevent the mis-
use of genetic material. Furthermore, as technological advances in genetics allow increasingly 
accurate prediction of phenotype and disease likelihood, it is likely that the genetic material 
contained within gametes will need progressively more stringent protection. An example of 
such measures includes the recently-enacted General Data Protection Regulation (GDPR), 
which legislates for the prevention of the misuse of such genetic data [62].
The societal effects of the growing popularity of cryopreservation must also be considered. 
More women than ever before are experiencing the ironic dichotomy of spending the vast 
majority of their reproductive years trying no ensure that they do not fall pregnant, but 
then finding themselves unable to conceive when they try to. As such, the landscape of this 
exploding field is increasingly commercial, providing increased funds to facilitate advances 
in treatment efficacy at the cost of advertising cryopreservative services as an insurance policy 
against age-related fertility decline. There is also a worrying increase in the number of com-
panies offering ‘social freezing’ as part of their employee benefit packages. This is a trend that 
propagates the misinformed idea that social cryopreservation guarantees a later pregnancy, 
and serves to perpetuate the societal pressure placed on women to delay childbearing [63]. 
The cost of such procedures (if not covered by insurance or a third party) is also a valid con-
sideration, with various cost benefit analyses finding contrasting conclusions on whether it is 
more, or less cost-effective to cryopreserve in one’s mid-twenties and return to them at age 40, 
Technique Description Evidence
In-vitro maturation 
(IVM) of immature 
oocytes
IVM aims to increase the yield of oocytes available for 
cryopreservation through the obtaintion of additional M2 oocytes 
from oocytes that would otherwise be discarded. Although data 
shows that approximately 35% of IVM oocytes can produce cleavage-
stage embryos when fertilised, and this method has been suggested to 
increase the efficacy of treatment cycles aimed at fertility preservation, 
there is currently insufficient data to support the systematic use of 
IVM techniques or the freezing of immature oocytes.
Oktay et al. [116]
Phoon et al. [117]
Selection via DNA 
fragmentation rate
It is clear that a both vitrification and slow-freeze protocols produce 
DNA lesions, either via full or partial fragmentation. Although 
modern analytical techniques can quantify this fragmentation 
(and resulting apoptotic induction), they most commonly result in 
destruction of the gamete in question. As such, although they may 
provide valuable information on the quality of a particular sample, 
they do not provide a solution for the accurate selection of gametes 
which may prove more viable that their morphologically-normal 
counterparts.
Valcarce et al. [118]
CPA equilibration 
temperatures
Changing the equilibration temperature with CPA and increasing 
the sucrose concentration added have both proven to be effective 
strategies to improve oocyte survival and fertilisation rates, 
respectively
Borini et al. [119]
Table 1. Methods of improving gamete selection when employing cryopreservation techniques.
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or just to attempt conventional IVF at age 40 [14, 64]. Whilst this is an important avenue of 
discussion, the superior success rates provided by the cryopreservation route are likely to 
provide a superior chance of obtaining a live birth.
While the risks associated with childbearing at an increased age may have the immedi-
ate downstream effects of reducing the incidence of certain genetic aberrations, it is also 
important to consider knock-on effects which may not be immediately obvious. It is pos-
sible that widespread societal gamete cryopreservation could unearth harmful novel ART-
mediated epigenetic alterations, or further promote the delay of childbearing age. Such 
effects would doubtless affect the composition of our society, and the manner in which 
it functions. Therefore, the future direction and regulations governing this area must be 
scrutinised to determine what should, and should not be permitted. This is a more complex 
ethical discussion that falls outside of the scope of this chapter, but should nonetheless be 
kept in mind.
3. Current status of embryo cryopreservation
Since the early days of in vitro fertilisation (IVF) 40 years ago, there have been remarkable 
advances in clinical and laboratory areas that have opened the door to different variants 
of standard IVF procedure [65, 66]. Improvements of ovarian stimulation protocols enable 
the collection of several mature oocytes, which associated with the improvement of the IVF 
techniques and optimization of embryo culture result in the obtention of a large number of 
embryos. Therefore, embryo cryopreservation was a necessary evolutionary step for IVF-
treatments with the first pregnancy after transfer of a frozen-thawed embryo being reported 
in 1984 [67]. Since then, embryo cryopreservation has become a widely used technic in 
assisted reproductive technology (ART), allowing the preservation of the remaining embryos 
following a fresh transfer for future pregnancies and as a modern tool to reduce multiple 
births by encouraging patients to transfer a single embryo [1, 68]. Additional indications for 
embryo cryopreservation are the embryo banking for preimplantation genetic screening, 
elective deferred embryo transfer, when the patient is at risk of a hyperstimulation and for 
fertility preservation [66, 69]. Thus, embryo cryopreservation greatly increased the safety and 
efficacy of IVF treatments and enable the later use of all the embryos obtained from a single 
oocyte pick-up.
Over the years, cryopreservation methods, protocols and stage at time of cryopreservation 
have changed, improving embryo cryopreservation techniques. Consequently, the number 
of frozen-thawed cycles increased worldwide [66, 70] with similar or even higher pregnancy 
rates compared with the transfer of fresh embryo [65, 70]. In Europe, the last report generated 
from registers by the European Society of Human Reproduction and Embryology (ESHRE) 
stated that 154,712 frozen-thawed cycles were performed in 2013, increasing the overall life 
birth rate by 6% [71].
Herein we will resume the evolution of the embryo cryopreservation methods, stage at which 
cryopreservation is performed and give an overview of the perinatal outcomes of frozen-
thawed embryo transfers.
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3.1. Methods of cryopreservation applied to embryos
Since the first reports of pregnancy and delivery after transfer of frozen-thawed embryos in the 
earlies 1980s [67, 72] various protocols of embryo cryopreservation were introduced. They mostly 
differ from each other in the type and concentration of cryoprotectants, equilibration timing, 
cooling rates and freezing devices [35]. Regardless of the cryopreservation method used, the goal 
is to suspend embryos in time by cooling embryos from ambient temperature to −196°C [73]. 
Nowadays slow freezing and vitrification are the two principal approaches for embryo cryo-
preservation, although vitrification has become favored over the last decade [35, 74].
In slow-freezing protocol the temperature is decreased sufficiently slowly to allow the ade-
quate cellular dehydration but also minimising the formation of intracellular ice. This is only 
possible through the use of a programmable freezing machine. With this method, the samples 
are first exposed to a quick cooling rate of 2°C/minute until they reach −7°C. Then extracellu-
lar ice crystal formation is induced manually (seeding) by touching the vial or straw with pre-
cooled forceps as far away from the embryos as possible. As consequence, more water leaves 
the embryo allowing cryoprotectants to enter. After the seeding, the temperature decreases 
slowly (0.3–1°C/minute) untill it reaches temperatures approximately −40°C and then rapidly 
to −150°C with a cooling rate of approximately 50°C/minute. The embryos are then stored in 
liquid nitrogen until use [35, 74].
Although the first pregnancies and birth were obtain with an embryo cryopreserved with 
dimethylsulphoxide (DMSO) as cryoprotectant [67, 72] births using other cryoprotectants, 
such as propanediol (PrOH) were soon reported [75, 76]. Since then, this has become the 
cryoprotectant more widely used in combination with sucrose for embryo cryopreserva-
tion by slow-freezing [35] (Table 2). The disadvantage of the slow-freezing method is the 
formation of ice crystals, increasing the risk of cell damage during thawing. Therefore, 
despite this method has being used for over 30 years in IVF laboratories and considered 
safe, since the concentrations of the cryoprotectants used to avoid ice crystal formation 





1.5 M PROH plus 0.1 M sucrose are 
included in the most commonly used 
protocols [74]
EG-based method was early proposed for 
vitrification of cleavage stage embryos [122]
DMSO-based method initially reported the lowest 
survival rate [123]
EG/DMSO/sucrose in open or close systems are the 
most commonly used cryoprotectants
Blastocysts Glycerol and sucrose as cryoprotectants 
are included in the most commonly used 
protocols [74]
EG and DMSO were the cryoprotectants used 
in the first pregnancy reported after blastocyst 
vitrification [124]
EG/DMSO/sucrose in open or close system are also 
used [97, 125]
Abbreviations: EG: ethylene glycol; DMSO: dimethylsulphoxide.
Table 2. Commonly used protocols for cryopreservation of cleavage stage human embryos and blastocysts.
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With vitrification, the ice formation is almost eliminated since the cells and the extracellular 
milieu are solidified into a glass-like state [77]. This method has an extremely high cooling rate in 
the range of 2500–30,000°C/minute till −196°C by immediate exposure to liquid nitrogen [74, 77]. 
Despite the high concentrations of cryoprotectants that this method requires, its potential 
toxicity is reduced by the short time of exposure and the small volume of cryoprotectants 
used [35]. As in the slow-freezing method different cryoprotectants were tested, leading to the 
current preferred combination of DMSO (15%), ethylene glycol (EG-15%) and sucrose (0.5 M) 
in a minimum volume (≤1 μl) [78] (Table 2). The biggest difference between vitrification pro-
tocols relates to the cooling and storage methods employed, with open system, involving 
direct embryo contact with the liquid nitrogen, or closed system involving specific devices to 
avoid direct contact with the liquid nitrogen [35].
With vitrification a laboratory can expect to obtain an increased embryo cryosurvival rate 
comparing to the slow-freezing method (Table 3), has well as a beneficial effect in the clinical 
pregnancy rate and live-birth rate per embryo transfer [35, 74, 79, 80]. Additionally, vitrifica-
tion method does not require any specific equipment and is less time consuming compared to 
slow-freezing. Consequently, many laboratories worldwide have completely replaced slow-
freezing with vitrification [35].
3.2. Cryopreservation at cleavage stage vs. blastocyst
The first pregnancy was obtained with an embryo cryopreserved at eight cells stage [67]. Since 
then the procedure has changed several times, with the current practice being to preserve either at 
the cleavage stage Day 2 or 3 of culture or at the stage of blastocyst at day 5 or 6 of culture, despite 
no clear evidence of which strategy is more beneficial for frozen-thawed embryo transfer [81, 82]. 
Since only few randomised controlled trials (RCTs) have been conducted to determine what stage 
of development optimises cumulative birth rate for the retrieval cycle, most of the available data 
about the timing of embryo cryopreservation is derived from outcomes of fresh cycles [73].
Despite the method of cryopreservation and embryo’s stage, the embryo selection for cryo-
preservation is based on their morphology and pre-freezing morphology is directly related 
with cryopreservation success and efficiency [83].
Cleavage stage Blastocyst stage
Day 2 Day 3 Day 5 Day 6
Morphology before 
cryopreservation [74, 81, 97]
≥4 blastomeres ≥6 blastomeres Blastocysts are scored according 
to expansion, inner mass and 
trophectoderm using Gardner 
scoring system – 3BB or better
<25% fragmentation
No multinucleate blastomeres
Morphology after thawing 
[74, 120]
≥50% intact blastomeres Scoring according to Gardner, as 
before cryopreservationHigher number of blastomeres after 24 h of  
culture
Expected survival [74, 121] 61.4–87.5% with slow freezing 76.3–88% with slow freezing
64–94% with vitrification 84–100% with vitrification
Table 3. Morphological aspects of embryos before/after cryopreservation and expected cryosurvival.
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For cleavage stage embryos, it is recommended that the embryos selected for cryopreser-
vation should have 4 cells at day 2 and 8 cells at day 3, less than 10% of fragmentation, 
stage specific cell size and no multinucleate blastomeres [84] (Table 3). After thawing, 
embryos with 100% intact blastomeres will have a higher implantation. However, in 
embryos with 50% or more cells intact post-thaw and with mitotic resumption, the num-
ber the cells at the transfer may be more predictive of the embryo’s ability to implant 
than the percentage of cells surviving at the time of thawing [85–87]. These parameters 
remain the most clinically important criteria to evaluate the implantation rate potential 
till today [83].
Advances in culture systems have made possible to prolong embryo culture until the 
embryo reaches the blastocyst stage. Thus, over the last decade blastocyst transfer at 
day 5/6 of culture has greatly increased and is seen for some as a “natural selection” of 
the most viable embryo, similar to the process during spontaneous conception [88, 89]. 
However, the clinical efficacy of blastocyst transfer over cleavage stage transfer is debat-
able. In fact, in 2016 a Cochrane meta-analysis reported an increase of clinical pregnancy 
and live birth after blastocyst transfer [82] but 1 year later another meta-analysis did not 
find any statistical difference in outcomes when comparing the transfer of embryos at the 
cleavage stage or blastocyst [90], the same results were previously described for cryopre-
served embryos [81].
As with cleavage stage embryos, assessment of blastocyst stage cryopreservation outcomes 
requires attention to variety of factors before cryopreservation and after thawing in addition 
to methodology. Outcomes have been shown to be dependent on pre-freeze quality of the 
blastocyst and time required to reach the blastocyst stage [91, 92].
The most commonly used blastocyst grading systems assigns scores to three morphologic 
aspects of the embryo: quality of inner cell mass—grades A, B, C; quality of the trophec-
toderm—grades A, B, C and degree of expansion (Table 3). Blastocyst score at the time of 
cryopreservation was associated with survival and implantation rates [93–95]. Other factors 
that may contribute to outcomes are the day the cryopreserved embryo reached the blastocyst 
stage [5, 6], whether the blastocoel was collapsed or not prior to cryopreservation, and evi-
dence of blastocoel re-expansion prior to transfer [96, 97].
3.3. Clinical and perinatal outcomes of pregnancies achieved using frozen-thawed 
embryo transfers
Frozen-thawed cycles increased during the last decade and a concern about the perinatal 
outcome also have risen [66]. Although embryo cryopreservation is a well established proce-
dure, long-term studies are still sparse [35]. Data are reassuring suggesting that pregnancies 
obtained from frozen embryos are not associated with an increased perinatal risk compared 
to fresh transfers [98–104]. Several reviews have indicated a slightly better result when 
frozen-thawed embryos were used compared to the fresh transfer, with reduced risks of 
preterm birth, small for gestational age babies, low birth weight babies and pre-eclampsia, 
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which could be justified by the endocrine milieu of the stimulation when the transfer is made 
fresh [70, 99, 102, 104].
Furthermore, a systematic review, published recently, confirmed that singleton babies born 
after the transfer of frozen-thawed embryos have higher weight at birth when compared to 
babies born after the transfer of fresh embryos, as well as a higher risk of hypertensive disor-
ders during pregnancy [70].
3.4. Future perspective: the freeze-all strategy
To further improve IVF outcomes, it has been suggested to freeze all the embryos obtained in 
a stimulation cycle and then plan a deferred transfer during a natural cycle or with hormone 
replacement with exogenous estradiol (E2) and progesterone (P) for endometrial priming 
[105, 106]. With this strategy, the frozen-thawed embryos are transferred into a more “phys-
iological milieu” which seems to improve implantation and outcomes compared to fresh 
transfer [106–108]. However, almost all the data was obtained in patients with high ovarian 
response patients and thus it was suggested that the freeze all strategy should be perform 
on patients with a risk of ovarian hyperstimulation syndrome (OHSS), since it was not clear 
if normal and poor responders will be the same benefits from freezing all the embryos [109].
A recent retrospective study using the general population has reported that 50.74% of 
patients using the freeze-all strategy achieved a live birth after the first complete cycle [105]. 
Additionally, another study indicated positive results in poor ovarian responders, and sug-
gested the freeze-all strategy as an alternative to cycle cancellation for these patients [110]. 
Despite these positive results, large multi-centre randomised controlled trials are needed to 
evaluate the freeze-all strategy [105, 110].
4. Conclusion
In conclusion, the cryopreservation of gametes and embryos is a rapidly developing field that 
demonstrates increasingly comparable success rates to those encountered in conventional 
IVF using fresh gametes or embryos. Aiming to provide reproductive autonomy for patients, 
it is intrinsically intertwined with both societal and ethical issues, and will doubtless play an 
increasingly central role in how we as a species reproduce over the coming decades. Research 
indicates also safety of reproductive treatments using cryopreserved gametes and embryos.
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